Posted by Michael Wonder on 27 Nov 2024
Lilly Canada remains steadfast in commitment to access options for patients amidst controversial CDA-AMC recommendation for Ebglyss (lebrikizumab)
19 November 2024 - Eli Lilly Canada is disappointed and strongly disagrees with Canada's Drug Agency (CDA-AMC)'s Final Recommendation for Ebglyss (lebrikizumab), published on Friday, 15 November 2024.
The CDA-AMC recommended that Ebglyss not be reimbursed by public drug plans, excluding Quebec, for the treatment of moderate to severe atopic dermatitis in adults and adolescents 12 years of age and older.
